Life Technologies Launches Cost-Effective Custom DNA Order Service for DNA Fragments up to One Kilobase
CARLSBAD, Calif. – May 23, 2013 -- Life Technologies Corporation announced today the introduction of GeneArt® Strings DNA Fragments, a cost-effective addition to the company’s custom gene synthesis services.
GeneArt® Strings are custom-ordered double-stranded segments of DNA that can be up to one kilobase (1,000 base pairs) in length. They offer the advantages of synthetic DNA – design flexibility and sequence optimization for robust and reliable expression – along with quick processing times and five to seven business day delivery. A three-tiered pricing system correlates with increasing size of the ordered fragment.
“GeneArt Strings DNA Fragments constitute a cost-effective option for researchers who seek to reduce their work time and do not need to order genes cloned to a vector,” said Nathan Wood, general manager and vice president of synthetic biology for Life Technologies.
GeneArt® Strings DNA Fragments can be edited, optimized, and ordered via the Life Technologies online order portal for a convenient and user-friendly customer experience.
GeneArt® products are for Research Use Only; not intended for diagnostic use.
About Life Technologies
Life Technologies Corporation is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact:
SOURCE Life Technologies Corporation